Immunotherapy targeting MSLN includes the use of tumor vaccines, antibody-based therapies, and adoptive T-cell therapy (CAR-T cells), some of which have demonstrated outstanding results in early clinical studies. This evidence concerns the gene MSLN and neoplasm.